BIND Goes Small to Make it Big With a Next-Gen Nanoparticle
BioWorld Insight Contributing Writer
Liposome nanoparticles have been in existence for nearly two decades. Doxil (doxorubicin liposomal), developed by Sequus Pharmaceuticals Inc., gained FDA approval in 1995. But liposomes have limited use because it's hard to target them to specific tissue and there are very few drugs that can be loaded into and released from liposomes.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST